Recombinant Viral CMV UL146/vCXC1 Protein, CF

• Reactivity: V
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Viral CMV UL146/vCXC1 Protein, CF Summary

• Details of Functionality: Measured by its ability to induce myeloperoxidase release from cytochalasin B-treated human neutrophils. Schröder, J.M. et al. (1987) J. Immunol. 139:3474. The ED₅₀ for this effect is 0.3-0.6 µg/mL. Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CXCR2. The ED₅₀ for this effect is 0.03-0.18 µg/mL.
• Source: E. coli-derived viral UL146/vCXC1 protein
  Thr23-Gly117
• Accession #: AAA85885
• N-terminal Sequence: Thr23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 11.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Viral CMV UL146/vCXC1 Protein, CF

• HHV5wtgp117
• UL146
• vCXC1
• vCXCL1
• Y18

Background

Cytomegalovirus (CMV), a member of the beta herpesvirus subfamily, typically causes subclinical or latent infections in the normal adult population. However, CMV can cause congenital disease during pregnancy and is a human opportunistic pathogen that affects immunocompromised individuals. The CMV genome has been shown to contain homologs of cellular immunomodulatory proteins, including US28 (a CC chemokine receptor) and a MHC class I homolog. Virulent CMV clinical isolates have also been shown to carry at least 19 genes, designated UL133 - UL151, that are not found in laboratory strains that have lost virulence characteristics. Two of these genes, UL146 and UL147, exhibit sequence similarity to CXC chemokines.

The CMV UL146 open-reading frame encodes a 117 amino acid residue precursor protein with a predicted 22 residues signal peptide that is cleaved to generate the mature protein. Recombinant UL146 has been shown to induce calcium mobilization, chemotaxis and degranulation of neutrophils.

1. Dairaghi, D. et al. (1998) Sem. Virol. 8:377.
2. Cha, T.A. et al. (1996) J. Virol.70:78.

Bioinformatics

• Uniprot:
  • AAA85885()